The $15 billion expansion of the Roche-Hansoh partnership signals a massive shift toward multi-program antibody-drug conjugate portfolios rather than traditional single-asset licensing deals. This momentous agreement, finalized in late 2026, represents a fundamental restructuring of how global
By integrating real-world environmental data with deep molecular analysis, a new study aims to provide a roadmap for early recognition of respiratory vulnerability in infants. Every year, thousands of families watch their infants struggle with severe viral infections like bronchiolitis or
Manufacturing failures can occur if patients receive lymphodepleting agents like bendamustine too close to the collection of their therapeutic T cells. This biological reality creates a high-stakes environment for oncologists managing relapsed/refractory multiple myeloma, where the timing of every
The persistent challenge of treating advanced HPV16-positive malignancies has driven medical science toward a more personalized approach that prioritizes early detection of treatment efficacy through minimally invasive methods. In the current landscape of oncology, researchers are increasingly
Data derived from the Phase 3 C-POST trial provided the empirical foundation for a new dosing strategy that aims to lower the physical and emotional strain of frequent cancer treatments. This recommendation from the Committee for Medicinal Products for Human Use marks a pivotal shift in how
The landscape of modern oncology is rapidly shifting toward molecular precision, leaving behind the era of broad treatments that often fail to address specific genetic drivers. Patients with P-loop and alpha-C helix compressing mutations have long lacked targeted front-line options, often falling
